Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AFPc332T |
Synonyms | |
Therapy Description |
AFPc332T comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting alpha-fetoprotein (AFP), which potentially induces killing of AFP-expressing tumor cells (PMID: 30561769, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFPc332T | Autologous genetically modified AFPc332 T cells|AFP-c332T|AFP c332T | AFPc332T comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting alpha-fetoprotein (AFP), which potentially induces killing of AFP-expressing tumor cells (PMID: 30561769, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Active, not recruiting | USA | GBR | FRA | ESP | 0 |